Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
PLX8394 Chemical Structure
|Product name: PLX8394|
|Cat. No.: HY-18972|
PLX8394 is a potent and selective inhibitor of B-RafV600E (IC50~5 nM).
IC50 value: ~5 nM
in vitro: PLX8394 potently inhibits phosphorylation of ERK1/2 in PRT #3 and PRT #4 cells in addition to parental cells. PLX8394 potently inhibits ERK1/2-driven GAL4-Elk1 reporter activity in PRT cells as well as parental cells. PLX8394 effectively reducs cyclin D3 and cyclin D1, phosphorylation of retinoblastoma protein, and expression of cyclin A2 in parental cells. PLX8394 reduces levels of these cell cycle markers in PRT #3 and PRT #4 cells. Consistent with these effects, PLX8394 inhibits EdU incorporation into PRT #3 and PRT #4 cells in S phase entry assays. PLX8394 inhibits ERK1/2 phosphorylation and the growth of vemurafenib-resistant cells harboring either a BRAF V600K/L505H double mutation or an transposon-induced, N-terminal truncated form of BRAF.
|M.Wt||542.53||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: ≥ 39 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||1.8432 mL||9.2161 mL||18.4322 mL|
|5 mM||0.3686 mL||1.8432 mL||3.6864 mL|
|10 mM||0.1843 mL||0.9216 mL||1.8432 mL|
AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.
B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM).
A B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.
BRAF inhibitor is a potent BRAF inhibitor.
Doramapimod (BIRB 796) is a highly selective p38(alpha) MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKC(alpha)/(beta)/(gamma).
GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well; no inhibition known to other protein kinases.
GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.
HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.
L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38(alpha), GSK3(beta) and Lck respectively.
LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
Other Countries & RegionsSee Worldwide Distributors